B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.85 +0.32 (+0.60%)
Streaming Delayed Price Updated: 12:45 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 448,447
Open 53.69
Bid (Size) 53.85 (4)
Ask (Size) 53.86 (2)
Prev. Close 53.53
Today's Range 53.50 - 53.97
52wk Range 42.63 - 55.72
Shares Outstanding 1,250,690,553
Dividend Yield 3.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis. 
Via Investor's Business Daily

Performance

YTD
+7.70%
+7.70%
1 Month
+7.38%
+7.38%
3 Month
+9.88%
+9.88%
6 Month
+17.58%
+17.58%
1 Year
+1.99%
+1.99%

More News

Read More
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Via MarketBeat
Exposures COVID-19
NASDAQ:SNY may be ready to breakout.
Via Chartmill
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Via Benzinga
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Via Benzinga
Exposures COVID-19
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
Via Benzinga
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
Where Will Novavax Be in 5 Years?
Via The Motley Fool
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Via Benzinga
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
Via InvestorPlace
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
Via InvestorPlace
Sanofi (SNY) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Via Benzinga
25 Best Artificial Intelligence Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Economy
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
Via Benzinga
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
Stable Blue-Chip Stocks to Buy Before Earnings Season
Via InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.